# DESCRIPTION

- introduce prostate cancer
- describe TNM classification
- classify prostate cancers into four stages
- describe periprostatic adipose tissue (PPAT)
- explain role of PPAT in prostate cancer
- describe adipose tissue composition
- explain role of adipocytes in energy fluctuations
- describe adipocyte secretions
- discuss link between obesity and prostate cancer
- introduce chemokines
- describe chemokine classification
- explain role of chemokines in cancer
- discuss CXCR4 and CXCL12 interaction
- describe role of CXCR4 in prostate cancer
- discuss CCR2 and CCL2 interaction
- describe role of CCR2 in prostate cancer
- introduce other chemokine receptors
- describe role of CCR1 and CCR3 in cancer
- discuss CCR3 expression in kidney tumors and melanoma
- describe preliminary study on CCR3 in prostate cancer
- discuss limitations of current studies
- introduce therapeutic strategy for localized tumors
- describe D'Amico classification
- explain need for new treatments
- introduce inventors' research
- describe role of CCR3 in local dissemination
- discuss in vitro experiments
- describe in vivo experiments
- discuss correlation between CCR3 expression and tumor aggressiveness
- introduce medullary adipocytes
- describe role of CCR3/CCL7 pathway in remote dissemination
- discuss interest of inhibiting CCR3 or CCL7
- describe increased CCL7 expression in obese subjects
- introduce inhibitor of CCL7 or CCR3 expression for treating prostate cancer
- define inhibitor of CCR3 expression
- specify shRNA targeting CCR3 gene
- specify antisense oligonucleotide targeting CCR3 gene
- define inhibitor of CCL7/CCR3 interaction
- specify competitive and non-competitive CCR3 antagonists
- specify organic molecules inhibiting CCL7/CCR3 interaction
- specify peptides inhibiting CCL7/CCR3 interaction
- specify antibodies targeted against CCR3 or CCL7
- specify peptidomimetics inhibiting CCL7/CCR3 interaction
- specify aptamers recognizing CCL7 or CCR3
- describe method for identifying inhibitors of CCL7/CCR3 interaction
- specify administration of inhibitors with pharmaceutically acceptable excipients
- describe methods and routes of administration of inhibitors
- determine dose of inhibitor used
- describe method for preventing or treating prostate cancer
- describe ex vivo method for determining degree of aggressiveness of prostate cancer tumor
- obtain sample of prostate tumor cells
- obtain sample of healthy prostate epithelium
- measure concentration of receptor CCR3 in sample of cells
- specify specific antibody for receptor CCR3
- determine reference concentration of receptor CCR3 in healthy prostate epithelium
- classify subject suffering from prostate cancer according to degree of aggressiveness

## Materials and Methods

### Antibodies, Inhibitors and Product Used

- list antibodies
- list inhibitors

### Cell Culture

- describe cell lines
- describe culture medium
- describe cell culture conditions
- describe TRAMP-C1P3 cell line
- describe RM1-BM cell line
- describe mature adipocytes

### Ex Vivo Differentiated Medullary Adipocyte Model

- describe medullary adipocyte model
- describe cell isolation
- describe differentiation protocol

### Human Medullary Adipocyte Samples

- describe sample collection

### Human Visceral Adipose Tissue Samples for Analysis of the Expression of CCL7 by Q-PCR

- describe sample collection

### Human Periprostatic Adipose Tissue Samples

- describe sample collection

### Human Yellow Marrow and Subcutaneous Adipose Tissue Samples

- describe sample collection

### Mouse Perigonadal Adipose Tissue Samples

- describe sample collection

### Measurement of Genic Expression by Q-PCR

- extract total RNA
- transcribe RNA to cDNA
- perform real-time PCR reaction
- normalize genic expression
- analyze expression of CCL7 gene
- compile primer sequences and concentrations
- digest adipose tissue with collagenase
- isolate primary adipocytes and SVF cells
- culture cells in DMEM medium
- sample conditioned medium
- count cells at end of experiment
- conduct human and mouse CCL7 assay using ELISA test
- analyze expression of chemokine receptors in tumor lines
- wash and fix tumor cells
- incubate with antibodies
- analyze by flow cytometry
- conduct Boyden chamber migration tests
- evaluate cell migration
- analyze conditioned media from adipocytes
- concentrate and separate proteins
- identify peptides and proteins
- inhibit expression of CCR3 using shRNA
- generate shRNA sequences
- transfect and select cells
- analyze expression of CCR3 gene

## Results

- introduce migration of prostate tumor cells against conditioned medium from adipocytes
- describe Boyden chamber migration tests
- show expression of receptors CCR2, CXCR1, CXCR2, CXCR4 by prostate cancer lines
- test functionality of receptors in migration of PC-3 cells against CM-Ad
- study specificity of CCR3 in migration of prostate cells against CM-Ad
- analyze migration of various epithelial tumor cells against CM-Ad
- show inhibition of migration by UCB35625 and antibodies blocking CCR3
- summarize results of migration tests

### The Ligand of CCR3, CCL7 is Involved in the Migration of Prostate Tumor Cells Against Conditioned Medium of Adipocytes

- conduct proteomic analysis of CM-Ad
- detect chemokines CXCL1, CXCL5, CXCL12, CCL2, CCL7, CCL9
- show CCL7 induces migration of PC-3 and Du-145 prostate cells
- inhibit migration by blocking antibody against CCR3 and CCL7
- prepare conditioned medium from perigonadal adipose tissue (AT-mu-PG) and periprostatic adipose tissue (AT-hu-PP
- detect CCL7 in conditioned media of AT-mu-PG and AT-hu-PP
- show migration of tumor cells against conditioned media
- inhibit migration by UCB35625 and antibodies blocking CCR3/CCL7 pathway
- summarize results of CCL7 involvement in migration
- discuss role of CCR3/CCL7 pathway in prostate cell migration
- conclude CCL7 is involved in migration of prostate tumor cells

### Validation of the Involvement of CCR3 in Migration in Response to Adipocyte Secretions in a Mouse Tumor Line Model (TRAMP-C1P3)

- validate CCR3 expression in TRAMP-C1P3 cells
- show CCL7 induces chemotaxis in TRAMP-C1P3 cells
- inhibit migration by UCB35625 and antibodies blocking CCR3/CCL7 pathway
- summarize results of validation of CCR3 involvement

### The Receptor CCR3 is Involved in Tumor Progression in Mouse Models In Vivo

- inject TRAMP-C1P3 cells into prostate of normal-weight and obese mice
- measure tumor size in normal-weight and obese mice
- show increased tumor size in obese mice
- inject m6CCR3 cells into prostate of normal-weight and obese mice
- measure tumor size in normal-weight and obese mice
- show decreased tumor size in m6CCR3 cells
- analyze histological sections of tumors
- summarize results of tumor progression in mouse models

### Immunohistochemical Quantification of the Vitamin B12 Transport Protein (TCH), Cell Surface Receptor (TCH-R) and Ki-67 in Human Tumor Xenografts.

- analyze expression of CCR3 in human prostate tumors
- correlate CCR3 expression with Gleason score and clinical parameters
- summarize results of immunohistochemical quantification

### Sphingosine Kinase-1 Activity and Expression in Human Prostate Cancer Resection Specimens.

- correlate CCR3 values with surgical treatment failure

### The Expression of the Receptor CCR3 Plays a Role in the Migration of Prostate Cancer Cells Induced by Medullary Adipocytes

- introduce two types of models
- describe medullary adipocytes differentiation
- demonstrate CCL7 secretion by medullary adipocytes
- show migration of PC-3 tumor cells induced by medullary adipocytes
- characterize RM1-BM prostate cancer line
- demonstrate CCL7-induced migration of RM1-BM cells
- show inhibition of migration by UCB35625 and blocking antibodies
- demonstrate human medullary adipocytes chemoattract human prostate tumor cells
- show regulation of CCR3/CCL7 pathway by obesity

